Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma

References

• CBTRUS. Primary brain tumors in the United States, 1998 – 2002. Central Brain Tumor Registry of the United States, Chicago, IL 2005
   Google Scholar
• Abrey L E, DeAngelis L M, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859–863
   PubMed Web of Science ®Google Scholar
• Batchelor T, Loeffler J S. Primary CNS lymphoma. J Clin Oncol 2006; 24: 1281–1288
   PubMed Web of Science ®Google Scholar
• DeAngelis L M, Seiferheld W, Schold S C, Fisher B, Schultz C J. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93 – 10. J Clin Oncol 2002; 20: 4643–4648
   PubMed Web of Science ®Google Scholar
• Lai R, Rosenblum M K, DeAngelis L M. Primary CNS lymphoma: a whole-brain disease?. Neurology 2002; 59: 1557–1562
   PubMed Web of Science ®Google Scholar
• McAllister L D, Doolittle N D, Guastadisegni P E, Kraemer D F, Lacy C A, Crossen J R, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000; 46: 51–60, discussion 60 – 61
   PubMed Web of Science ®Google Scholar
• Poortmans P M, Kluin-Nelemans H C, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003; 21: 4483–4488
   PubMed Web of Science ®Google Scholar
• Ervin T, Canellos G P. Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer 1980; 45: 1556–1557
   PubMed Web of Science ®Google Scholar
• Reni M, Ferreri A J. Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 2001; 80(Suppl 3)B113–B117
   PubMed Web of Science ®Google Scholar
• Nguyen P L, Chakravarti A, Finkelstein D M, Hochberg F H, Batchelor T T, Loeffler J S. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005; 23: 1507–1513
   PubMed Web of Science ®Google Scholar
• Plotkin S R, Betensky R A, Hochberg F H, Grossman S A, Lesser G J, Nabors L B, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004; 10: 5643–5646
   PubMed Web of Science ®Google Scholar
• Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 2004; 40: 1682–1688
   PubMed Web of Science ®Google Scholar
• Voloschin A D, Wen P, Hochberg F, Batchelor T. Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma: final report. Neurology 2004; 62: 478, (abstract)
   Google Scholar
• Fischer L, Thiel E, Klasen H A, Birkmann J, Jahnke K, Martus P, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006; 17: 1141–1145
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Brugger W, Bamberg M, Kuker W, Dichgans J, Weller M. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 2000; 54: 1707–1708
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, Lopez-Guillermo A, Bessell E M, Nomdedeu B, Montserrat E, Graus F. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 2003; 70: 219–224
   PubMed Web of Science ®Google Scholar
• Khalfallah S, Stamatoullas A, Fruchart C, Proust F, Delangre T, Tilly H. Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transplant 1996; 18: 1021–1023
   PubMed Web of Science ®Google Scholar
• Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001; 19: 742–749
   PubMed Web of Science ®Google Scholar
• del Giglio A, Costa L J, Pinczowski H, Varella P C, Luzzi J R, Neves P, et al. Pilot study of the combination of melphalan, carboplatin and etoposide as a conditioning regimen for relapsed lymphoma patients. Acta Haematol 1999; 102: 56–58
   PubMed Web of Science ®Google Scholar
• Tyson R M, Siegal T, Doolittle N D, Lacy C, Kraemer D F, Neuwelt E A. Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma 2003; 44: 627–633
   PubMed Web of Science ®Google Scholar
• Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004; 89: 753–754
   PubMed Web of Science ®Google Scholar
• Wong E T, Tishler R, Barron L, Wu J K. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004; 101: 139–145
   PubMed Web of Science ®Google Scholar
• Enting R H, Demopoulos A, DeAngelis L M, Abrey L E. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004; 63: 901–903
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126
   PubMed Web of Science ®Google Scholar
• Sehn L H, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027–5033
   PubMed Web of Science ®Google Scholar
• Pels H, Schulz H, Manzke O, Hom E, Thall A, Engert A. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 2002; 59: 213–216
   PubMed Web of Science ®Google Scholar
• Rubenstein J L, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101: 466–468
   PubMed Web of Science ®Google Scholar
• Rubenstein J L, Rosenberg J, Damon L E. High dose methotrexate plus rituximab (anti-CD-20) monoclonal antibody in the treatment of primary CNS lymphoma. Neuro-oncology 1999; 1: 336, (abstract 174)
   Google Scholar
• Witzig T E, Gordon L I, Cabanillas F, Czuczman M S, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–2463
   PubMed Web of Science ®Google Scholar
• Press O W, Rasey J. Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol 2000; 27: 62–73
   PubMed Web of Science ®Google Scholar
• Witzig T E, Flinn I W, Gordon L I, Emmanouilides C, Czuczman M S, Saleh M N, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262–3269
   PubMed Web of Science ®Google Scholar
• Doolittle N D, Jahnke K, Belanger R, Nance R WJ, Lacy C, Tyson R M, et al. Enhanced delivery to the central nervous system of monoclonal antibody based therapy in relapsed primary central nervous system lymphoma. Neurooncology 2006; 8: 180, (abstract)
   Google Scholar
• Neuwelt E A, Dahlborg S A. Blood-brain barrier disruption in the treatment of brain tumors: clinical implications. Implications of the Blood-Brain Barrier and Its Manipulation: Clinical Aspects, E A Neuwelt. Plenum, New York 1989; 195–262
   Google Scholar
• Doolittle N D, Muldoon L L, Brummett R E, Tyson R M, Lacy C, Bubalo J S, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 2001; 7: 493–500
   PubMed Web of Science ®Google Scholar
• Neuwelt E A, Brummett R E, Doolittle N D, Muldoon L L, Kroll R A, Pagel M A, et al. First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther 1998; 286: 77–84
   PubMed Web of Science ®Google Scholar
• Smith J R, Rosenbaum J T, Wilson D J, Doolittle N D, Siegal T, Neuwelt E A, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002; 109: 1709–1716
   PubMed Web of Science ®Google Scholar
• Macdonald D R, Cascino T L, Schold S C, Jr, Cairncross J G. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277–1280
   PubMed Web of Science ®Google Scholar
• Muldoon L L, Neuwelt E A. BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models. J Neurooncol 2003; 65: 49–62
   PubMed Web of Science ®Google Scholar
• Stemmler J, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Brain metastases in HER2-overexpressing metastatic breast cancer: comparative analysis of trastuzumab levels in serum and cerebrospinal fluid. J Clin Oncol 2006; 24: 64S, (abstract)
   Google Scholar
• Neuwelt E A, Thrun L A, Walker-Rosenfeld S, Cave A T, Muldoon L L. Effect of antigenic heterogeneity on the efficacy of enhanced delivery of antibody-targeted chemotherapy in a human lung cancer intracerebral xenograft model in rats. Neurosurgery 2003; 53: 1406–1412, discussion 1412 – 1413
   PubMed Web of Science ®Google Scholar
• Remsen L G, Trail P A, Hellstrom I, Hellstrom K E, Neuwelt E A. Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery 2000; 46: 704–709
   PubMed Web of Science ®Google Scholar